Assertio Holdings, Inc. (ASRT)
| Market Cap | 58.46M |
| Revenue (ttm) | 124.96M |
| Net Income (ttm) | -21.58M |
| Shares Out | 95.77M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | 10.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 295,628 |
| Open | 0.6270 |
| Previous Close | 0.6211 |
| Day's Range | 0.6063 - 0.6270 |
| 52-Week Range | 0.5100 - 1.8000 |
| Beta | 0.57 |
| Analysts | Strong Buy |
| Price Target | 3.08 (+407.58%) |
| Earnings Date | May 5, 2025 |
About ASRT
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older;... [Read more]
Financial Performance
In 2024, Assertio Holdings's revenue was $124.96 million, a decrease of -17.83% compared to the previous year's $152.07 million. Losses were -$21.58 million, -93.50% less than in 2023.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ASRT stock is "Strong Buy." The 12-month stock price forecast is $3.08, which is an increase of 407.58% from the latest price.
News
Assertio to Participate in the iAccess Alpha Virtual Best Ideas Conference on March 25-26, 2025
LAKE FOREST, Ill., March 20, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that Brendan O'Grady, Chief Executive Officer, will present a...
Assertio Holdings, Inc. (ASRT) Q4 2024 Earnings Call Transcript
Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2024 Earnings Conference Call March 12, 2025 4:30 PM ET Company Participants Matthew Kreps - IR Brendan O'Grady - CEO Ajay Patel - CFO Conference Call Partici...
Assertio Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth Quarter Net Product Sales $29.6 Million, Cash Flow from Operations of $11.5 Million Full Year Net Product Sales $120.8 Million, Rolvedon Sales Exceed $60.0 Million Full Year Cash Flow from Oper...
Assertio Holdings, Inc. to Report Fourth Quarter and Full Year 2024 Financial Results on March 12, 2025
LAKE FOREST, Ill., March 05, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) today announced that it will release fourth quarter and full year 2024 financ...
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...
Assertio Holdings, Inc. Appoints Mark Reisenauer to Its Board of Directors
LAKE FOREST, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...
Assertio Announces Results of Rolvedon® (eflapegrastim-xnst) injection Same-Day Dosing Clinical Study
LAKE FOREST, Ill., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...
Buxton Helmsley Calls for Senate Hearing on Well-Documented Evident Clinical Data Fraud at Assertio
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that recently inverted its long equit...
Assertio Holdings, Inc. (ASRT) Q3 2024 Earnings Call Transcript
Call Start: 16:30 January 1, 0000 5:03 PM ET Assertio Holdings, Inc. (NASDAQ:ASRT) Q3 2024 Earnings Conference Call November 11, 2024 04:30 PM ET Company Participants Matthew Kreps - Darrow Associate...
Assertio Reports Third Quarter 2024 Financial Results
Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE) -...
Buxton Helmsley Releases Evidence of Product-Related Fraud at Assertio
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has inverted its long equity pos...
Assertio Provides Response to Letter from Short-seller
Claims about Rolvedon and Assertio's Accounting Practices are False and Baseless Short-seller's Press Release is Another Improper Attempt to Enrich Himself at Assertio's Expense Company Considering Ta...
Buxton Helmsley Issues Letter to Assertio Stockholders Disclosing Inversion to Short Position Following Board Refusal to Address Product-Related Fraud
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc. (together with certain of its affiliates, “BHG” or “we”), a New York City-based investment fund manager that has now inverted its long equity...
Assertio to Participate in the Maxim Group Healthcare Virtual Summit on October 15, 2024
LAKE FOREST, Ill., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...
Assertio Holdings: Management Change Could Improve Comeback Chances
After losing exclusivity with its prior flagship drug, pharma firm Assertio Holdings (ASRT) is angling for a comeback with a new flagship drug product. However, Assertio's latest fiscal results were m...
Assertio to Participate in the HC Wainwright and Lake Street Conferences in New York City September 10-12, 2024
LAKE FOREST, Ill., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering...
Assertio Holdings, Inc. (ASRT) Q2 2024 Earnings Call Transcript
Assertio Holdings, Inc. (NASDAQ:ASRT) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Matthew Kreps - Darrow Associates, IR Brendan O'Grady - Chief Executive Officer A...
Assertio Reports Second Quarter 2024 Financial Results
Second Quarter Total Net Product Sales of $30.7 Million Rolvedon Growth Continues, with $15.1 million in Net Product Sales $7.4 Million in Cash Flow from Operations, Cash and Short-Term Investments In...
Assertio Holdings, Inc. to Report Second Quarter 2024 Financial Results on August 7, 2024
LAKE FOREST, Ill., July 24, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...
Buxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings, Inc.
NEW YORK--(BUSINESS WIRE)--The Buxton Helmsley Group, Inc., a significant shareholder of Assertio Holdings, Inc. (NASDAQ: ASRT), today issued the following letter to the company's Board of Directors. ...
Assertio: An Extremely Asymmetric Bet Skewed To The Upside
Assertio Holdings, Inc. shares present a significant upside potential due to ongoing turnaround efforts and proven success in monetizing underappreciated pharma assets. The merger with Spectrum Pharma...
Assertio to Participate in the Sidoti Small Cap Conference on June 12, 2024
LAKE FOREST, Ill., June 05, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering ...
Assertio to Participate in Benchmark Healthcare Conference on May 21-22
LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering d...
BUXTON HELMSLEY RELEASES LETTER FROM CERTIFIED FRAUD EXAMINER ATTESTING TO DISCLOSURE FAILURES AND DEFICIENCIES BY ASSERTIO HOLDINGS BOARD OF DIRECTORS
Letter Expresses Several Significant Concerns and Recommends That Further Investigation is Warranted Urges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Ei...
Assertio to Participate in AGP Healthcare Conference on May 21
LAKE FOREST, Ill., May 16, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering d...